Zinc Oxide Nanoparticles Ameliorate Dimethylnitrosamine-Induced Renal Toxicity in Rat

Examining the quaternary ammonium chitosan Schiff base-ZnO nanocomposite's potential as protective therapy for rats' cisplatin-induced hepatotoxicity

BACKGROUND

Despite cisplatin's long history as a cornerstone in cancer therapy, both acquired chemoresistance and significant impacts on healthy tissues limit its use. Hepatotoxicity is one of its side effects. Adjunct therapies have shown promise in not only attenuating liver damage caused by cisplatin but also in enhancing the efficacy of chemotherapy. In this context, a new quaternary ammonium chitosan Schiff base (QACSB) was synthesized and applied as an encapsulating agent for the in-situ synthesis of QACSB-ZnO nanocomposite.

MATERIAL AND METHODS

Thirty male albino rats were classified into Group 1 (control) distilled water, Group 2 (Cisplatin-treated) (12 mg/kg, i.p), and Group 3 (QACSB-ZnO NCs/cisplatin-treated) (150 mg/kg/day QACSB-ZnO NCs, i.p) for 14 days + a single dose of cisplatin. Liver functions, tissue TNF-α, MDA, and GSH were measured as well as histopathological and immunohistochemical studies were performed.

RESULTS

The QACSB-ZnO NCs significantly restore liver functions, tissue TNF-α, MDA, and GSH levels (p < 0.001). Histopathological examination showed patchy necrosis in the cisplatin-treated group versus other groups. The QACSB-ZnO NCs showed a weak TGF-β1 (score = 4) and a moderate Bcl-2 immunohistochemistry expression (score = 6) versus the CP group.

CONCLUSIONS

QACSB-ZnO NCs have been shown to protect the liver from cisplatin-induced hepatotoxicity.

Advanced (bio)fouling resistant surface modification of PTFE hollow-fiber membranes for water treatment

Membrane surface treatment to modify anti-(bio)fouling resistivity plays a key role in membrane technology. This paper reports on the successful use of air-stimulated surface polymerization of dopamine hydrochloride incorporated ZnO nanoparticles (ZnO NPs) for impeding the intrinsic hydrophobicity and low anti-(bio)fouling resistivity of polytetrafluoroethylene (PTFE) hollow-fiber membranes (HFMs). The study involved the use of pristine and polydopamine (Pdopa) coated PTFE HFMs, both with and without the presence of an air supply and added ZnO NPs. Zeta potential measurements were performed to evaluate the dispersion stability of ZnO NPs prior to immobilization, while morphological characterization and time-dependency of the Pdopa growth layer were illustrated through scanning electron microscopy. Pdopa surface polymerization and ZnO NPs immobilization were confirmed using FT-IR and EDX spectroscopy. Transformation of the PTFE HFM surface features to superhydrophilic was demonstrated through water contact angle analysis and the stability of immobilized ZnO NPs assessed by ICP analysis. Anti-fouling criteria and (bio)fouling resistivity performance of the surface-modified membranes were assessed through flux recovery determination of bovine serum albumin in dead-end filtration as well as dynamic-contact-condition microbial evaluation against Staphylococcus spp. and Escherichia coli, respectively. The filtration recovery ratio and antimicrobial results suggested promising surface modification impacts on the anti-fouling properties of PTFE HFM. As such, the method represents the first successful use of air-stimulated Pdopa coating incorporating ZnO NPs to induce superhydrophilic PTFE HFM surface modification. Such a method can be extended to the other membranes associated with water treatment processes.

The combined effect of zinc oxide nanoparticles and milrinone on acute renal ischemia/reperfusion injury in rats: Potential underlying mechanisms

AIM

To investigate the efficacy of zinc oxide nanoparticles (ZnO-NPs) and/or milrinone (MIL) on renal ischemia/reperfusion injury (I/RI) in rats and their possible underlying mechanisms.

MATERIALS AND METHODS

Forty-eight adult male Sprague-Dawley albino rats were randomly assigned into six equal-sized groups (n = 8): normal control, sham-operated, I/R group (45 min/24 h), ZnO-NPs group (10 mg/Kg i.p.), MIL group (0.5 mg/Kg i.p.), and ZnO-NPs + MIL group in the same previous doses.

KEY FINDINGS

In comparison to the I/R-operated group, administration of either ZnO-NPs or MIL significantly decreased serum creatinine and urea concentrations, and renal vascular permeability (p < 0.05). The oxidative stress was significantly declined, as evidenced by increased GPx, CAT, and SOD activities and decreased MDA and NO concentrations. Renal expressions of TNF-α, NF-κB, KIM-1, NGAL, and caspase-3 decreased significantly, while Nrf2 increased significantly. Histopathology investigation revealed improvement with minimal renal lesions and fibrosis after ZnO-NPs or MIL treatments. The combined treatments synergistically improved the studied parameters more than either treatment alone. These findings were validated by molecular modeling, which revealed that MIL inhibited TNF-α, NF-kB, caspase-3, KIM-1 and NGAL.

SIGNIFICANCE

Both ZnO-NPs and MIL exerted cytoprotective effects against acute renal I/RI, and a combination of both was found to be even more effective. This renoprotective effect is suggested to be mediated through activation of Nrf2 and the prevention of the NF-κB activation-induced oxidative stress and inflammation, which may strengthen the potential role of ZnO-NPs or MIL in renal I/RI protection during surgical procedures.

Implication of Nanoparticles to Combat Chronic Liver and Kidney Diseases: Progress and Perspectives

Liver and kidney diseases are the most frequently encountered problems around the globe. Damage to the liver and kidney may occur as a result of exposure to various drugs, chemicals, toxins, and pathogens, leading to severe disease conditions such as cirrhosis, fibrosis, hepatitis, acute kidney injury, and liver and renal failure. In this regard, the use of nanoparticles (NPs) such as silver nanoparticles (AgNPs), gold nanoparticles (AuNPs), and zinc oxide nanoparticles (ZnONPs) has emerged as a rapidly developing field of study in terms of safe delivery of various medications to target organs with minimal side effects. Due to their physical characteristics, NPs have inherent pharmacological effects, and an accidental buildup can have a significant impact on the structure and function of the liver and kidney. By suppressing the expression of the proinflammatory cytokines iNOS and COX-2, NPs are known to possess anti-inflammatory effects. Additionally, NPs have demonstrated their ability to operate as an antioxidant, squelching the generation of ROS caused by substances that cause oxidative stress. Finally, because of their pro-oxidant properties, they are also known to increase the level of ROS, which causes malignant liver and kidney cells to undergo apoptosis. As a result, NPs can be regarded as a double-edged sword whose inherent therapeutic benefits can be refined as we work to comprehend them in terms of their toxicity.